Weekly high-dose leucovorin versus low-dose leucovorin combined with fluorouracil in advanced colorectal cancer: Results of a randomized multicenter trial

Journal of Clinical Oncology

Volumn 14, Issue 8, 1996, Pages 2274-2279

  Jager E ^a   Heike, M ^a   Bernhard, H ^a   Klein, O ^a   Bernhard, G ^a   Lautz, D ^a   Michaelis, J ^a   Meyer zum Buschenfelde K H ^a   Knuth, A ^a  

^a KRANKENHAUS NORDWEST   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; FOLINIC ACID;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0029813416     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.8.2274     Document Type: Article

References (21)

1. Silverberg E: Cancer statistics. CA 38:3-20, 1989
2. Valone FH, Friedman MA, Wittlinger PS, et al: Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: A randomized trial of the Northern California Oncology Group. J Clin Oncol 7:1427-1436, 1989
3. Petrelli N, Douglass HO, Herrera L, et al: The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial. J Clin Oncol 7:1419-1426, 1989
4. Heike M, Wölfel T, Meyer zum Büschenfelde K-H, et al: Adjuvante und palliative Therapie kolorektaler Karzinome. Deutsch Med Wochenschr 119:778-785, 1994
5. Rustum YM, Trave F, Zakrzewski SF, et al: Biochemical and pharmacologic basis for potentiation of 5-fluorouracil action by leucovorin. NCI Monogr 5:165-170, 1987
6. Moran RG, Scanion KL: Schedule-dependent enhancement of the cytotoxicity of fluoropyrimidines to human carcinoma cells in the presence of folinic acid. Cancer Res 51:4618-4623, 1991
7. Doroshow JH, Multhauf P, Leong L, et al: Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment od advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J Clin Oncol 8:491-501, 1990
8. Erlichman C, Fine S, Wang A, et al: A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 6:469-475, 1988
9. Gerstner J, O'Connell MJ, Wienand HS, et al: A prospectively randomized clinical trial comparing 5FU combined with either high or low dose leucovorin for the treatment of advanced colorectal cancer. Proc Am Soc Clin Oncol 10:134, 1991 (abstr)
10. Poon MA, O'Connell MJ, Moertel CG, et al: Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 10:1407-1418, 1989
11. Piedbois P, Buyse M, Rustum Y, et al: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 10:896-903, 1992
12. de Gramont A, Bosset JF, Milan C, et al: A prospectively randomized trial comparing 5FU bolus with low dose folinic acid (FUFOLld) and 5FU bolus plus continuous infusion with high dose folinic acid (LV5FU2) for advanced colorectal cancer. Proc Am Soc Clin Oncol 14:194, 1995 (abstr)
13. Poon MA, O'Connell MJ, Wieand HS, et al: Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 9:1967-1972, 1991
14. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
15. O'Brian PC, Fleming TR: A multiple testing procedure for clinical trials. Biometrics 35:549-556, 1979
16. Peto R, Pike MC, Armitage P: Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 35:1-39, 1977
17. Valsecchi R, Labianca R, Cascinu S, et al: High dose (HD) versus low dose (LD) L-leucovorin (LLV) as a modulator of 5-days 5-fluorouracil (5FU) in advanced colorectal cancer (ACC): A GISCAD phase III study. Proc Am Soc Clin Oncol 14:195, 1995 (abstr)
18. York M, Greco FA, Figlin RA, et al: A randomized phase III trial comparing 5-FU with or without interferon alfa 2a for advanced colorectal cancer. Proc Am Soc Clin Oncol 12:200, 1993 (abstr)
19. Köhne CH, Wilke H, Hecker H, et al: Interferon-alpha does not improve the antineoplastic efficacy of high-dose infusional 5-fluorouracil plus folinic acid in advanced colorectal cancer. Ann Oncol 6:461-466, 1995
20. Group CAS: Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. J Clin Oncol 13:921-928, 1995
21. Sobrero A, Aschele C, Guglielmi A, et al: High activity and low toxicity of alternating bolus and continuous infusion 5-fluorouracil with schedule-oriented biochemical modulation in advanced colon cancer patients. Proc Am Soc Clin Oncol 13:588, 1994 (abstr)